Summary
This Cureus article reviews the evidence for omega-3 polyunsaturated fatty acid (EPA and DHA) supplementation as an adjunct or alternative intervention for children with attention-deficit hyperactivity disorder. The authors appear to summarise trial findings on symptom reduction, dosing considerations and biological plausibility, likely concluding that omega-3 supplementation confers modest benefits that may complement, rather than replace, standard pharmacological treatment.
UK applicability
Findings are broadly transferable to UK paediatric practice, where dietary intakes of long-chain omega-3s are typically below recommended levels and NICE guidance already acknowledges dietary factors in ADHD management. The review may inform UK clinicians and parents considering nutritional adjuncts, though it does not replace UK-specific clinical guidelines.
Key measures
ADHD symptom rating scales (e.g. Conners, ADHD-RS); EPA/DHA dosage (mg/day); blood/plasma fatty acid concentrations; behavioural and cognitive outcomes
Outcomes reported
The paper examines the effects of omega-3 PUFA (EPA/DHA) supplementation on attention, hyperactivity and behavioural symptoms in children diagnosed with ADHD. It likely synthesises evidence on symptom improvement, blood fatty acid status and tolerability.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.